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Mesial temporal lobe epilepsy with Mesial temporal lobe epilepsy with hippocampal sclerosis
(MTLE-HS) is a common epilepsy syndrome accounting for approximately 20% of people with
epilepsy.1 It typically shows electroclinical features indicative of seizure onset in the mesial or
limbic structures of the temporal lobe, i.e., epigatric/visceral, autonomic, psycho-affective, and
sensorial symptoms, including déjà vu.1 Awareness is generally preserved at onset, but loss of
consciousness may also occur, with motionless stare and oro-alimentary, vocal, or gestural
automatisms, eventually followed by a convulsive seizure. EEGs show anterior or mid-temporal
epileptic abnormalities combined with focal slowing. Hippocampal sclerosis (HS) is de-
monstrable on coronal MRI sequences by a unilateral (or asymmetrical) decrease in hippocampal
volume and an increase in signal onT2-weighted sequences. The neuropathologic hallmark ofHS
is a combination of atrophy and astrogliosis of the amygdala, hippocampus, uncus, para-
hippocampal gyrus, and the entorhinal cortex.1 The diagnosis of MTLE-HS is crucial because it is
often uncontrolled by antiseizure drugs but typically responsive to resective surgery.2,3
The etiology of MTLE-HS remains largely elusive. Although generally perceived as an acquired
disorder, a few familial cases have been reported,4–6 suggesting complex inheritance, similar to
that widely accepted for genetic generalized epilepsies. Hitherto, this condition is an appropriate
target for contemporary approaches to complex disorders, such as genome-wide association
studies for common genetic variants or deep sequencing for rare variants. A relatively recent
association study, including ;1,000 patients with MTLE-HS compared with ;7,500 controls,
identified a robust association with a polymorphic marker in the sodium channel gene SCN1A.7
In this issue of Neurology Genetics®, Wong et al.8 investigated the role of rare and de novo
genetic variants in MTLE-HS by whole-exome sequencing (WES) performed in a small well-
characterized cohort of Han Chinese patients from Hong Kong clinically homogeneous as to
seizure semiology, ictal/interictal EEG recordings, and high-definition brain MRI studies. Age
at onset of epilepsy was ≥2 years. As control, the authors used WES data from 692 Hong Kong
Han Chinese participants with no history of developmental or neuropsychiatric disorders.
Association studies of rare variants (frequency of minor allele <1% in population databases)
were performed at gene or gene-set levels by comparing the total amounts of variation found in
individual genes or in groups of clinically or functionally connected genes, respectively, in cases
and controls. Moreover, in a subgroup of patients, of whom both parents were available, rare
variant analysis of parent-proband trios was performed to uncover de novo variants not
transmitted by either parent and potentially recessive mutations inherited by both parents.
Overall, WES data from 47 patients (26 females), including 23 trios, ledWong et al.8 to identify
rare and de novo variants in a number of genes. Notably, compared to population controls,
significant enrichment of rare variants was observed in SEC24B, a gene involved in vesicle
trafficking and development, whereas gene-set association analysis showed variant enrichment
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in the fragile X mental retardation protein (FMRP)-related
group of genes, which comprises hundreds of genes regulated
by the FMRP protein, including the mammalian target of
rapamycin (mTOR) pathway. In addition, analysis of trios
revealed 21 de novo variants, many of which are known to be
associated with different neuropsychiatric disorders. These
results, however, while providing useful hints for future
studies, should be considered with caution on a clinical/
diagnostic ground because of the low statistical power of the
cohort investigated. Indeed, the enrichment of variants
revealed in SEC24B, based on 3/47 variants identified in the
patients vs 1/652 in the controls, only indicates a statistical
trend to be confirmed in studied of larger patient cohorts;
variant enrichment in the FMRP gene set might reflect the
higher number of genes making up this gene group as com-
pared to the other gene sets investigated. Also, the conclusion
that FMRP targets by its putative interaction with the mTOR
pathway may play a pathogenic role in MTLE-HS sounds
attractive, but it is speculative. However, the frequency of de
novo mutations detected in the patients (21/23 trios) does
not exceed that expected in the general population (approx-
imately 1 de novo variant per individual). Some of them affect
genes such as ROBO4, NLGN3, and CEP170B, which have
been found to harbor variants in autism spectrum disorder,
but their involvement in epilepsy awaits confirmatory studies.
Overall, no major hit emerged for MTLE-HS from this study,
supporting the view that the genetic architecture underlying
MTHE-HS is complex and that MTLE-HS and other neu-
ropsychiatric disorders may have shared biology. The major
limitation of this study is the relatively small cohort of in-
vestigated patients, particularly the small number of analyzed
trios, which is unlikely to produce positive results, especially if
considering the likely polygenic nature of the disease. Genetic
epilepsies include over 30% of all epilepsy syndromes. Next-
generation sequencing has proven to be effective in identify-
ing mutations for mendelian, single-gene disorders.9 By
contrast, this technique have showed so far limited success in
the identification of variants causing more complex pheno-
types where the phenotypes are more heterogeneous, and it is
unclear whether they result from the action of a single gene,
multiple genes, or a complex interaction between the genetic
and environmental factors.
The increasing development of experimental tools and bio-
informatics analysis for a large-scale evaluation of gene ex-
pression may help overcome this limitation to confirm the
preliminary findings emerging from this WES study. In a re-
cent study, the group of E. Aronica examined the pathologic
cellular pathways involved in different phases of epilepto-
genesis in human and animal hippocampus.10 This analysis
revealed involvement of several key pathogenic pathways
underlying epileptogenesis, including inflammation, gliosis
and deregulation of the extracellular matrix. Better un-
derstanding of gene expression and regulation during the
course of epileptogenesis in MTLE may eventually produce
significant advances for the development of preventive
treatment for this common chronic neurologic disease.
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